Research Analysts Offer Predictions for ZVRA Q3 Earnings

Key Points

• HC Wainwright revised its Q3 2025 earnings per share estimate for Zevra Therapeutics from (0.07) to (0.06) and maintains a "Buy" rating with a price target of $26.00.
• Zevra Therapeutics reported a Q2 loss of (0.06) EPS, significantly missing the expected $1.43 EPS, while revenues exceeded expectations at $25.88 million.
• The stock currently has a consensus "Buy" rating from nine analysts and an average price target of $23.71, indicating positive market sentiment despite recent rating changes.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities research analysts at HC Wainwright upped their Q3 2025 earnings estimates for shares of Zevra Therapeutics in a note issued to investors on Wednesday, August 13th. HC Wainwright analyst B. Folkes now expects that the company will earn ($0.06) per share for the quarter, up from their previous forecast of ($0.07). HC Wainwright currently has a "Buy" rating and a $26.00 target price on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Zevra Therapeutics' Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at $1.14 EPS and FY2028 earnings at $2.42 EPS.

ZVRA has been the topic of a number of other reports. JMP Securities cut their price target on shares of Zevra Therapeutics from $19.00 to $18.00 and set a "market outperform" rating on the stock in a report on Wednesday, August 13th. Wall Street Zen downgraded shares of Zevra Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 20th. Cantor Fitzgerald increased their price target on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th. Finally, Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $23.71.

Zevra Therapeutics Stock Performance

Shares of NASDAQ:ZVRA traded down $0.19 during midday trading on Friday, reaching $9.01. The company had a trading volume of 1,330,933 shares, compared to its average volume of 734,420. The company's 50 day moving average price is $10.56 and its 200 day moving average price is $8.77. The company has a current ratio of 7.85, a quick ratio of 7.81 and a debt-to-equity ratio of 0.52. The stock has a market cap of $505.73 million, a P/E ratio of -42.90 and a beta of 1.87. Zevra Therapeutics has a 52-week low of $6.19 and a 52-week high of $13.16.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Ameritas Investment Partners Inc. grew its holdings in shares of Zevra Therapeutics by 30.0% in the second quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company's stock worth $49,000 after purchasing an additional 1,280 shares during the last quarter. BNP Paribas Financial Markets bought a new position in shares of Zevra Therapeutics in the fourth quarter worth approximately $53,000. GAMMA Investing LLC grew its holdings in shares of Zevra Therapeutics by 20,564.1% in the first quarter. GAMMA Investing LLC now owns 8,059 shares of the company's stock worth $60,000 after purchasing an additional 8,020 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Zevra Therapeutics by 617.5% in the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company's stock worth $88,000 after purchasing an additional 8,552 shares during the last quarter. Finally, Creative Planning bought a new position in shares of Zevra Therapeutics in the second quarter worth approximately $92,000. 35.03% of the stock is currently owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.